Lonial Sagar
Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Rd, Building C, Room 4004, Atlanta, GA, 30322, USA.
Cancer Treat Res. 2016;169:195-205. doi: 10.1007/978-3-319-40320-5_11.
Treatment for myeloma has dramatically changed over the past decade, as has overall survival, due in large part to the development of new targeted agents. While proteasome inhibitors and immunomodulatory agents have contributed to improved outcomes, additional new options remain an unmet medical need. Classes of emerging agents include those targeting epigenetics, such as histone deacetylase inhibitors, monoclonal antibodies, and other emerging targets, such as kinesin spindle protein (KSP) inhibitors, cyclin dependent kinase (CDK) inhibitors, and nuclear protein export inhibitors. Future treatment approaches will need to identify how and when to incorporate these treatment options to optimally treat patients with relapsed or refractory myeloma.
在过去十年中，骨髓瘤的治疗方法发生了巨大变化，总生存率也有所改变，这在很大程度上归功于新型靶向药物的研发。虽然蛋白酶体抑制剂和免疫调节剂已有助于改善治疗效果，但仍有其他新的治疗选择未得到满足。新兴药物类别包括靶向表观遗传学的药物，如组蛋白去乙酰化酶抑制剂、单克隆抗体，以及其他新兴靶点，如驱动蛋白纺锤体蛋白（KSP）抑制剂、细胞周期蛋白依赖性激酶（CDK）抑制剂和核蛋白输出抑制剂。未来的治疗方法需要确定如何以及何时纳入这些治疗选择，以最佳地治疗复发或难治性骨髓瘤患者。
